GalNAc-Lipid Nanoparticles Enable Non-LDLR Dependent Hepatic Delivery of a CRISPR Base Editing Therapy
Summary by Nature
3 Articles
3 Articles
All
Left
Center
1
Right
GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy
Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated endocytosis. For patients lacking sufficient low-density lipoprotein receptor activity, such as those with homozygous familial hypercholesterolemia, an alternate strategy is needed. Here we show the use of structure-guided rational design in a series of mouse and no…
·United Kingdom
Read Full ArticleAdvanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group
In the past decade, precise targeting through genome editing has emerged as a promising alternative to traditional therapeutic approaches. Genome edit…
·Amsterdam, Netherlands
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium